Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MediWound Ltd. - Ordinary Shares (NQ:MDWD)

18.37 +0.05 (+0.27%)
Streaming Delayed Price Updated: 11:15 AM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
From MediWound Ltd.
Via GlobeNewswire
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
From MediWound Ltd.
Via GlobeNewswire
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
From MediWound Ltd.
Via GlobeNewswire
Earnings Scheduled For August 14, 2025
 
Via Benzinga
Earnings Outlook For MediWound
 
Via Benzinga
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From MediWound Ltd.
Via GlobeNewswire
MediWound Revenue Jumps 43% in Q2
Via The Motley Fool
MediWound (MDWD) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
MediWound Ltd (NASDAQ:MDWD) Reports Mixed Q2 2025 Results with Revenue Growth but Wider-Than-Expected Losses
MediWound's Q2 2025 results show mixed performance: $5.7M revenue (+43% QoQ) missed estimates, but shares rose 5% on NexoBrid growth and EscharEx progress. 
Via Chartmill
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Second Quarter 2025 Financial Results
From MediWound Ltd.
Via GlobeNewswire
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
MediWound (MDWD) Q1 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
Earnings Scheduled For May 21, 2025
 
Via Benzinga
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report First Quarter 2025 Financial Results
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
From MediWound Ltd.
Via GlobeNewswire
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
Earnings Scheduled For March 19, 2025
 
Via Benzinga
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
From MediWound Ltd.
Via GlobeNewswire
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From MediWound Ltd.
Via GlobeNewswire
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
From MediWound Ltd.
Via GlobeNewswire
Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.